



Sobrevida Actuarial





PROBABILITY OF SURVIVAL AFTER BMT FOR CML IN CHRONIC PHASE BY DONOR TYPE AND DISEASE DURATION - 1990-1996 -



INDICATIONS FOR ALLOGENEIC BLOOD AND MARROW TRANSPLANTS REGISTERED WITH THE IBMTR, 1998-2003


- Worldwide -






Talpaz, M. et al. N Engl J Med 2006;354:2531-2541

ANNUAL NUMBERS OF BLOOD AND MARROW TRANSPLANTS WORLDWIDE 1970-2000



Respuesta 100% → NO



Nuevas Drogas



HIV: Modelo Terapéutico

A + B
↓
Respuesta

Pérdida Efecto
↗

C + D
↓
Respuesta